The impact of COVID-19 disease on the natural course of cirrhosis: Before and after starting vaccination.
COVID-19
cirrhosis
clinical course
death
vaccination
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
09
2022
accepted:
09
12
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Cirrhosis has been reported as an important risk factor for death in coronavirus disease 2019 (COVID-19) disease. In this study, we aimed to investigate the effects of COVID-19 on the natural course of cirrhosis before and after starting vaccination. The cirrhosis patients in our cohort ( Between March 2020 and January 2021, 36 of the 140 cirrhosis patients had developed COVID-19. Cirrhosis (+)/COVID-19 (+) and Cirrhosis (+)/COVID-19 (-) groups did not differ in terms of age, CCI and MELD-Na scores, or gender. There were six deaths in the Cirrhosis (+)/COVID-19 (+) group and five in the Cirrhosis (+)/COVID-19 (-) group [6/36 (16.6%) vs. 5/104 (4.8%); In our cirrhotic cohort, COVID-19 disease was associated with 16% mortality in the pre-vaccination period. COVID-19 vaccination prevents serious illness and death due to COVID-19 in cirrhotic patients.
Sections du résumé
Background
UNASSIGNED
Cirrhosis has been reported as an important risk factor for death in coronavirus disease 2019 (COVID-19) disease. In this study, we aimed to investigate the effects of COVID-19 on the natural course of cirrhosis before and after starting vaccination.
Methods
UNASSIGNED
The cirrhosis patients in our cohort (
Results
UNASSIGNED
Between March 2020 and January 2021, 36 of the 140 cirrhosis patients had developed COVID-19. Cirrhosis (+)/COVID-19 (+) and Cirrhosis (+)/COVID-19 (-) groups did not differ in terms of age, CCI and MELD-Na scores, or gender. There were six deaths in the Cirrhosis (+)/COVID-19 (+) group and five in the Cirrhosis (+)/COVID-19 (-) group [6/36 (16.6%) vs. 5/104 (4.8%);
Discussion
UNASSIGNED
In our cirrhotic cohort, COVID-19 disease was associated with 16% mortality in the pre-vaccination period. COVID-19 vaccination prevents serious illness and death due to COVID-19 in cirrhotic patients.
Identifiants
pubmed: 36816721
doi: 10.3389/fmed.2022.1039202
pmc: PMC9932027
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1039202Informations de copyright
Copyright © 2023 Keskin, Oral, Sahin, Kav and Parlak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Liver Int. 2022 Jun;42(6):1287-1296
pubmed: 35107848
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 2020 Nov 19;71(16):2089-2098
pubmed: 32361738
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Hepatol. 2021 Dec;75(6):1434-1439
pubmed: 34454993
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
J Viral Hepat. 2022 Jan;29(1):4-20
pubmed: 34352133
Nat Rev Gastroenterol Hepatol. 2021 May;18(5):348-364
pubmed: 33692570
Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9
pubmed: 34509643
J Viral Hepat. 2021 Jan;28(1):4-11
pubmed: 33190321
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
J Hepatol. 2021 Mar;74(3):567-577
pubmed: 33035628
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1469-1479.e19
pubmed: 32950749
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
J Hepatol. 2020 Nov;73(5):1231-1240
pubmed: 32553666
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
Intern Med J. 2022 Nov;52(11):1891-1899
pubmed: 35555962
J Clin Exp Hepatol. 2019 Mar-Apr;9(2):162-170
pubmed: 31024197